Dare Bioscience (NASDAQ:DARE)‘s stock had its “buy” rating restated by analysts at Roth Capital in a note issued to investors on Sunday, AnalystRatings.com reports. They presently have a $4.00 price objective on the biotechnology company’s stock. Roth Capital’s price objective indicates a potential upside of 296.04% from the stock’s previous close.

Several other research firms have also recently issued reports on DARE. Maxim Group reissued a “buy” rating and issued a $3.00 target price on shares of Dare Bioscience in a research note on Thursday, June 18th. ValuEngine cut Dare Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, July 8th. Aegis reissued a “market perform” rating and issued a $5.00 target price on shares of Dare Bioscience in a research note on Sunday. Brookline Capital Management started coverage on Dare Bioscience in a research note on Tuesday, April 28th. They issued a “buy” rating and a $7.50 target price on the stock. Finally, Dawson James reissued a “buy” rating and issued a $3.00 target price on shares of Dare Bioscience in a research note on Sunday. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Dare Bioscience has an average rating of “Buy” and an average target price of $4.50.

Shares of NASDAQ:DARE opened at $1.01 on Friday. The stock’s 50-day moving average price is $1.02 and its 200-day moving average price is $1.05. Dare Bioscience has a 12-month low of $0.69 and a 12-month high of $2.22. The stock has a market capitalization of $26.51 million, a P/E ratio of -1.15 and a beta of 1.82.

Dare Bioscience (NASDAQ:DARE) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.16. As a group, research analysts expect that Dare Bioscience will post -0.61 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Dare Bioscience stock. UBS Group AG acquired a new position in Dare Bioscience Inc (NASDAQ:DARE) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 38,502 shares of the biotechnology company’s stock, valued at approximately $32,000. UBS Group AG owned 0.15% of Dare Bioscience at the end of the most recent reporting period. 3.50% of the stock is currently owned by institutional investors and hedge funds.

About Dare Bioscience

Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.

Further Reading: How accurate is the Rule of 72?

Analyst Recommendations for Dare Bioscience (NASDAQ:DARE)

Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.